Key Insights• According to the research report, "China Antacids Market Outlook, 2031," published by Actual Market Research, the China Antacids Market is expected to reach a market size of more than 1.03 Billion by 2031.• A major insight is the strong performance of magnesium-aluminium carbonate, particularly in chewable-tablet form. According to data, sales of magnesium-aluminium carbonate chewable tablets across China’s three major terminals and six major markets exceeded RMB 900 million in 2024, and increased 5.03% in 2025. It was the No. 1 chemical antacid product in the category. The competitive base is also broadening as 58 companies had production approvals for magnesium-aluminium carbonate chewable tablets, 46 had passed China’s quality-and-efficacy consistency evaluation, while 6 additional companies were under review through the generic-drug Category 4 filing route.• In July 2026, Chongqing Yao Pharmaceutical received approval for its magnesium-aluminium carbonate chewable tablet, becoming the company's first antacid product. MiNei reported that total sales of magnesium-aluminium carbonate products exceeded RMB 1 billion in 2025, and that retail pharmacies accounted for 63% of the product's sales in 2025.• China's antacid market is increasingly shaped by generic-drug quality requirements, consistency evaluation and domestic product development. A particularly notable example is Chongqing Huapont Pharmaceutical's magnesium-aluminium carbonate product: the company reports that its chewable tablet became China's first magnesium-aluminium carbonate product to pass generic-drug quality-and-efficacy consistency evaluation in August 2019.

It subsequently won the second round of China's national centralized drug procurement in January 2020, with only two companies winning for that product at the time. The product has subsequently won multiple renewals after the initial procurement period.Market Outlook• The market outlook is favorable for combination antacids, chewable/fast-dissolving formats and alginate-based reflux products, rather than only conventional single-ingredient tablets. Global clinical guidance recognizes antacids and alginate-antacid combinations as options for rapid, generally short-term or intermittent relief of reflux symptoms. China's competitive landscape is likely to favor products offering multi-symptom relief, better taste, convenient dosage forms and differentiated mechanisms, while basic products face greater generic and price competition. At the same time, the large number of approved magnesium-aluminium carbonate manufacturers indicates that future value creation will increasingly depend on brand strength, distribution, manufacturing efficiency and formulation differentiation rather than market entry alone.• The next phase is likely to combine domestic pharmaceutical expansion, regulatory-driven consolidation and stronger retail/e-commerce competition. New entrants such as Chongqing Yao Pharmaceutical and Sunflower Pharmaceutical are expanding into magnesium-aluminium carbonate, while established players such as Huapont Pharmaceutical already have mature antacid portfolios.

The market should therefore become more competitive on price, consistency-evaluation status, procurement access and pharmacy/e-commerce distribution. For manufacturers, the opportunity is to scale qualified products through China's retail network while using digital channels to build OTC consumer awareness.• The Chinese Society of Gastroenterology is an important professional body for digestive-disease clinical guidance, while the Chinese Pharmaceutical Association is a major national professional organization relevant to pharmaceutical science and industry. Key companies include Chongqing Huapont Pharmaceutical, Chongqing Yao Pharmaceutical, Sunflower Pharmaceutical and multinational OTC players such as Haleon and Bayer. Recent competitive activity from Sunflower and Chongqing Yao is particularly notable because both are entering/expanding in the high-value magnesium-aluminium carbonate segment.Market DynamicsDriver: High obesity rates and lifestyle-induced GERD prevalenceAccording to reports by the Chinese Society of Gastroenterology and the National Health Commission of China, the incidence of reflux esophagitis has doubled over the past decade. With over 50% of Chinese adults now classified as overweight or obese a major physiological risk factor that increases intra-abdominal pressure the clinical demand for immediate acid-neutralizing and suppressive therapies has surged across both urban retail and hospital settingsChallenge: Over-reliance on PPIs and rising regulatory scrutinyUnlike Western markets where fast-acting neutralizing antacids (like aluminum/magnesium salts and calcium carbonates) dominate initial self-medication, Chinese consumers historically opt straight for PPIs (e.g., omeprazole, rabeprazole). However, growing regulatory scrutiny surrounding the side effects of prolonged self-medication such as bone density loss, gut microbiota disruption, and kidney complications is forcing health authorities to strictly monitor self-medication practices and PPI over-prescription, creating friction for overall category expansion.Trend: Strategic integration of traditional Chinese medicine (TCM) hybrid formulationsChinese consumers increasingly show a preference for natural, non-systemic solutions to long-term digestive care.

Manufacturers are capitalizing on this by creating dual-action hybrid products pairing rapid-acting chemical antacids with botanical extract ingredients (such as Herba Pogostemonis, Acorus calamus, or Rhizoma Coptidis) designed to buffer stomach acid instantly while soothing gastric inflammation and restoring internal balance.Procurement and Industry Impact • China’s centralized Volume-Based Procurement (VBP) policy has fundamentally reshaped the pricing structure of gastrointestinal drugs. Hospital-tier procurement of prescription-grade PPIs and acid reducers has seen aggressive price reductions often between 50% to 80% per unit during national tenders forcing foreign multinationals to shift their primary sales strategies away from public hospital systems and pivot heavily toward retail pharmacies and direct-to-consumer e-commerce channels.• Digital procurement platforms have become a primary sales growth vector for digestive remedies in China. Online pharmacy channels (such as JD Health, AliHealth, and Meituan Medicine) are registering continuous annual digital sales expansions of over 20% for OTC digestive care. This shift enables manufacturers to bypass traditional multi-tiered regional distribution networks and sell directly to consumers across Tier 3 and Tier 4 cities.• China stands as the largest single antacid market within the Asia-Pacific (APAC) landscape. Market share metrics indicate that China accounts for approximately 35.5% to 43% of the total Asia-Pacific antacids regional volume. This market scale heavily impacts global raw material supply chains, as Chinese pharmaceutical suppliers produce and export a major share of the world's Active Pharmaceutical Ingredients (APIs) for antacid formulations, including aluminum hydroxide, magnesium carbonate, and sodium bicarbonate.Segment AnalysisChina Antacids Market By Drug Class• Acid neutralizers remain an important component of gastrointestinal self-care in China because they provide direct, short-term relief by neutralizing existing gastric acid.

Calcium-, magnesium- and aluminium-based ingredients can be positioned for occasional heartburn, acid indigestion and upper-GI discomfort. Their appeal is strongest when consumers want immediate symptomatic relief rather than a longer treatment course. China's prescription/non-prescription classification system allows non-prescription medicines to be purchased and used without a physician's prescription, supporting the role of self-care products.• Proton Pump Inhibitors (PPIs) occupy a more sustained acid-control position because they suppress gastric acid secretion instead of neutralizing acid already present. They are particularly relevant to recurrent GERD, reflux oesophagitis and acid-related ulcer disease. Recent Chinese research continues to emphasize rational PPI utilization: a 2026 study from a northwest Chinese hospital described PPI utilization stewardship as an important issue because of concerns around inappropriate prescribing and pharmaceutical expenditure.• H2 antagonists provide an alternative acid-suppression mechanism by blocking histamine H2 receptors on gastric acid-producing cells. Their positioning is more suitable for selected patients seeking acid reduction without necessarily moving directly to prolonged PPI therapy.

In China's increasingly structured medicine-classification environment, the commercial opportunity for individual H2-antagonist products depends on their approved indication, dosage and prescription/non-prescription classification.• Pro-motility agents represent a specialized gastrointestinal-treatment segment because they primarily influence gastric emptying and gastrointestinal movement rather than directly neutralizing acid. They can be relevant when reflux symptoms coexist with delayed gastric emptying or motility abnormalities. Their use is consequently more clinically directed than conventional antacid self-medication.• Combination formulations are important because Chinese consumers with upper-GI symptoms may experience heartburn together with regurgitation, bloating or gas. Combining acid-neutralizing ingredients with alginates or anti-gas components can provide a broader symptom-management proposition. Combination products also give manufacturers opportunities to differentiate mature acid-control products through multi-symptom positioning and simplified dosing.China Antacids Market By Dosage Form• Tablets and chewables are particularly suitable for China's consumer self-care environment because they provide portable, standardized dosing and convenient administration. Chewable products are useful for consumers seeking rapid symptom relief after meals or while away from home.

The non-prescription classification framework also supports self-selection for medicines that have been approved for OTC use.• Liquid suspensions provide an alternative for consumers who prefer liquids or have difficulty swallowing tablets. They can accommodate multiple active ingredients and provide flexibility in dose formulation. Suspension stability, uniform distribution of active ingredients, flavour and accurate measurement are important product-development considerations.• Powders provide a flexible non-tablet format that can be dispersed or dissolved before administration. They may appeal to consumers seeking rapidly prepared gastrointestinal relief, although preparation requirements can make them less convenient than ready-to-use liquids or chewables. Moisture-resistant packaging and clear Chinese-language dosing instructions are therefore important.• Gels and syrups offer smooth administration and can be particularly useful for formulations incorporating alginates or other reflux-barrier ingredients. The gel-based approach can provide a physical barrier against reflux in addition to the acid-relief function, creating a differentiated proposition compared with conventional acid neutralizers.• Gummies and other formats represent a more consumer-oriented development opportunity within China's gastrointestinal self-care category.

Gummies can improve portability and provide an approachable administration experience, although achieving sufficient quantities of conventional antacid ingredients while maintaining acceptable taste, texture and stability can be technically challenging. Effervescent and rapidly dispersible formats offer additional opportunities for differentiation through convenience.China Antacids Market By Indication• Gastroesophageal Reflux Disease (GERD) is an important indication for China's broader acid-control market. A large population-based survey involving 16,078 adults found symptom-defined GERD in 3.1% of participants using the Montreal criteria. Prevalence varied substantially across the five surveyed regions, from 1.7% in Guangzhou to 5.1% in Wuhan, while prevalence was 3.8% in rural areas versus 2.4% in urban areas. These regional differences create a more geographically diverse treatment environment than a single national prevalence figure might suggest.• Heartburn is a major consumer-facing indication because it is recognizable and can encourage consumers to seek pharmacy-based or OTC treatment without a formal GERD diagnosis. The Chinese population study recorded reflux symptoms at least weekly in 5.2% of respondents, considerably higher than the 3.1% meeting the study's stricter GERD definition.

This distinction demonstrates why the broader heartburn and acid-indigestion population can be substantially larger than the diagnosed GERD segment.• Peptic ulcer represents a more medically managed indication than occasional heartburn. PPIs and other acid-suppressive therapies have a more important disease-management role because ulcer treatment generally requires attention to the underlying cause as well as acid reduction. Conventional antacids can provide symptomatic relief but should not be viewed as substitutes for appropriate ulcer-directed treatment.• Others include dyspepsia, acid indigestion, epigastric discomfort, sour stomach and overlapping upper-GI symptoms. These conditions are particularly relevant to consumer self-care because people may initially seek treatment based on symptoms rather than a confirmed diagnosis. The difference between the 5.2% weekly reflux-symptom prevalence and 3.1% symptom-defined GERD prevalence in the large Chinese survey illustrates the breadth of the symptom-led market.China Antacids Market By Distribution Channel• Retail pharmacies remain strategically important because consumers can obtain non-prescription medicines through regulated retail channels and seek advice from pharmacists or other qualified pharmaceutical professionals. China's classification framework divides medicines into prescription and non-prescription categories, with non-prescription products available for consumer self-selection.

Retailers distributing Class A non-prescription medicines are required to have appropriately qualified pharmacists or pharmaceutical technicians.• Hospital pharmacies serve a more clinically supervised segment involving patients with diagnosed GERD, peptic ulcers, reflux complications and other gastrointestinal conditions. Their demand is therefore more strongly influenced by physician diagnosis, hospital formularies and treatment protocols than by spontaneous OTC purchasing. The distinction is especially relevant for PPIs and other acid-control medicines that may be used for longer treatment courses.• Online pharmacies / E-commerce have become an increasingly structured distribution channel under China's online-drug regulations. The NMPA's online-sales provisions require online drug sellers to be qualified market authorization holders or drug distributors, while prescription-drug sales require authentic prescriptions and real-name registration. Online retailers must also provide pharmaceutical services through legally qualified pharmacists or other pharmaceutical professionals.• China's e-commerce environment therefore provides convenience for repeat purchases of familiar gastrointestinal medicines while maintaining significant regulatory oversight. Online retailers must clearly distinguish prescription and non-prescription medicines, display relevant qualifications and maintain systems for quality, traceability, storage, delivery and adverse-reaction reporting.

This makes regulatory compliance and product authenticity important competitive factors for online antacid distribution.Considered in this report• Historic Year: 2020• Base year: 2025• Estimated year: 2026• Forecast year: 2031Aspects covered in this report• Antacids Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Drug Class• Acid Neutralizers• Proton Pump Inhibitors (PPIs)• H2 Antagonists• Pro-Motility Agents• Combination FormulationsBy Dosage Form• Tablets & Chewables• Liquid Suspensions• Powders• Gels & Syrups• Gummies & OtherBy Indication• Gastroesophageal Reflux Disease• Heartburn• Peptic Ulcer• OthersBy Distribution Channel• Retail Pharmacies• Hospital Pharmacies• Online Pharmacies / E-Commerce.